Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation (Q38174585)

30 August 2017

Rationale of personalized immunosuppressive medication for hepatocellular carcinoma patients after liver transplantation (English)

1 reference

30 August 2017

liver transplantation

1 reference

based on heuristic

inferred from title

hepatocellular carcinoma

1 reference

Qiuwei Pan

6

0 references

Maikel P Peppelenbosch

object named as

Maikel P Peppelenbosch

5

0 references

Herold J Metselaar

3

object named as

Herold J Metselaar

1 reference

30 August 2017

Kan Chen

1

1 reference

PubMed ID

24376158

30 August 2017

Kwan Man

2

1 reference

PubMed ID

24376158

30 August 2017

Harry L A Janssen

4

1 reference

30 August 2017

27 January 2014

1 reference

30 August 2017

Liver Transplantation

1 reference

30 August 2017

20

1 reference

30 August 2017

3

1 reference

30 August 2017

261-269

1 reference

Recommendations for liver transplantation for hepatocellular carcinoma: an international consensus conference report

30 August 2017

1 reference

Increased incidence of early de novo cancer in liver graft recipients treated with cyclosporine: an association with C2 monitoring and recipient age.

21 January 2018

1 reference

Cyclosporine induces cancer progression by a cell-autonomous mechanism.

21 January 2018

1 reference

RAD001 (everolimus) inhibits tumour growth in xenograft models of human hepatocellular carcinoma

21 January 2018

1 reference

Indications and management of everolimus after liver transplantation.

21 January 2018

1 reference

A prospective randomised, open-labeled, trial comparing sirolimus-containing versus mTOR-inhibitor-free immunosuppression in patients undergoing liver transplantation for hepatocellular carcinoma

21 January 2018

1 reference

Homotransplantation of the liver

21 January 2018

1 reference

Impact of steroids on hepatitis C virus replication in vivo and in vitro.

21 January 2018

1 reference

Glucocorticoid-induced long-term remission in primary cerebral lymphoma: case report and review of the literature

21 January 2018

1 reference

The role of corticosteroids in the treatment of pain in cancer patients

21 January 2018

1 reference

Early steroid withdrawal after liver transplantation for hepatocellular carcinoma

21 January 2018

1 reference

The steroid and thyroid hormone receptor superfamily

21 January 2018

1 reference

Expression of bbc3, a pro-apoptotic BH3-only gene, is regulated by diverse cell death and survival signals

21 January 2018

1 reference

Microarray analysis uncovers the induction of the proapoptotic BH3-only protein Bim in multiple models of glucocorticoid-induced apoptosis

21 January 2018

1 reference

Distinct glucocorticoid receptor transcriptional regulatory surfaces mediate the cytotoxic and cytostatic effects of glucocorticoids

21 January 2018

1 reference

Selective regulation of bone cell apoptosis by translational isoforms of the glucocorticoid receptor

21 January 2018

1 reference

Glucocorticoid receptor-mediated apoptosis: mechanisms of resistance in cancer cells

21 January 2018

1 reference

Biological effects of cyclosporin A: A new antilymphocytic agent

21 January 2018

1 reference

A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. FK506 Kidney Transplant Study Group

21 January 2018

1 reference

Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens

21 January 2018

1 reference

Cyclosporin versus tacrolimus as primary immunosuppressant after liver transplantation: a meta-analysis.

21 January 2018

1 reference

Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence

21 January 2018

1 reference

Role of immunosuppression and tumor differentiation in predicting recurrence after liver transplantation for hepatocellular carcinoma: a multicenter study of 412 patients

21 January 2018

1 reference

Virus-drug interactions--molecular insight into immunosuppression and HCV.

21 January 2018

1 reference

Cyclosporine A promotes in vitro migration of human first-trimester trophoblasts via MAPK/ERK1/2-mediated NF-κB and Ca2+/calcineurin/NFAT signaling

21 January 2018

1 reference

Immunotoxicologic effects of cyclosporine on tumor progression in models of squamous cell carcinoma and B-cell lymphoma in C3H mice

21 January 2018

1 reference

Sirolimus inhibits growth of human hepatoma cells alone or combined with tacrolimus, while tacrolimus promotes cell growth

21 January 2018

1 reference

Calcineurin regulation of the mammalian G0/G1 checkpoint element, cyclin dependent kinase 4.

21 January 2018

1 reference

Use of mycophenolate mofetil in liver transplantation: a literature review.

21 January 2018

1 reference

Molecular mechanisms of the antiangiogenic and antitumor effects of mycophenolic acid

21 January 2018

1 reference

IMP dehydrogenase inhibitor mycophenolate mofetil induces caspase-dependent apoptosis and cell cycle inhibition in multiple myeloma cells

21 January 2018

1 reference

Mycophenolate mofetil inhibits tumor growth and angiogenesis in vitro but has variable antitumor effects in vivo, possibly related to bioavailability

21 January 2018

1 reference

The necrotic signal induced by mycophenolic acid overcomes apoptosis-resistance in tumor cells

21 January 2018

1 reference

Proteome analysis and morphological studies reveal multiple effects of the immunosuppressive drug mycophenolic acid specifically resulting from guanylic nucleotide depletion

21 January 2018

1 reference

Phase I clinical trial of the inosine monophosphate dehydrogenase inhibitor mycophenolate mofetil (cellcept) in advanced multiple myeloma patients.

21 January 2018

1 reference

A preclinical and clinical study of mycophenolate mofetil in pancreatic cancer

21 January 2018

1 reference

Prospective registry-based observational cohort study of the long-term risk of malignancies in renal transplant patients treated with mycophenolate mofetil

21 January 2018

1 reference

The long and winding road to rational treatment of cancer associated with LKB1/AMPK/TSC/mTORC1 signaling

21 January 2018

1 reference

Phase 1/2 study of everolimus in advanced hepatocellular carcinoma

21 January 2018

1 reference

Randomised clinical trial: comparison of two everolimus dosing schedules in patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation

21 January 2018

1 reference

Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

Effects of the mTOR inhibitor sirolimus in patients with hepatocellular and cholangiocellular cancer

21 January 2018

1 reference

Phase II study of sirolimus in treatment-naive patients with advanced hepatocellular carcinoma.

21 January 2018

1 reference

Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma.

21 January 2018

1 reference

The TOR pathway: a target for cancer therapy

21 January 2018

1 reference

The mTOR pathway in hepatic malignancies

21 January 2018

1 reference

An expanding role for mTOR in cancer

21 January 2018

1 reference

Rictor, a novel binding partner of mTOR, defines a rapamycin-insensitive and raptor-independent pathway that regulates the cytoskeleton

21 January 2018

1 reference

Rapamycin-FKBP specifically blocks growth-dependent activation of and signaling by the 70 kd S6 protein kinases

21 January 2018

1 reference

Prolonged rapamycin treatment inhibits mTORC2 assembly and Akt/PKB

21 January 2018

1 reference

Autophagy: shaping the tumor microenvironment and therapeutic response.

21 January 2018

1 reference

Interferon-γ induces autophagy with growth inhibition and cell death in human hepatocellular carcinoma (HCC) cells through interferon-regulatory factor-1 (IRF-1)

21 January 2018

1 reference

mTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.

21 January 2018

1 reference

Autophagy contributes to the survival of CD133+ liver cancer stem cells in the hypoxic and nutrient-deprived tumor microenvironment

21 January 2018

1 reference

mTOR and cancer: insights into a complex relationship

21 January 2018

1 reference

Sorafenib in advanced hepatocellular carcinoma

21 January 2018

1 reference

Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial

21 January 2018

1 reference

Personalized molecular targeted therapy in advanced, recurrent hepatocellular carcinoma after liver transplantation: a proof of principle.

21 January 2018

1 reference

Sorafenib extends the survival time of patients with multiple recurrences of hepatocellular carcinoma after liver transplantation

21 January 2018

1 reference

Sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.

21 January 2018

1 reference

Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.

21 January 2018

1 reference

Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.

21 January 2018

1 reference

Integrating sorafenib into an algorithm for the management of post-transplant hepatocellular carcinoma recurrence.

21 January 2018

1 reference

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

21 January 2018

1 reference

Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature

21 January 2018

1 reference

High toxicity of sorafenib for recurrent hepatocellular carcinoma after liver transplantation

21 January 2018

1 reference

Phase I study investigating everolimus combined with sorafenib in patients with advanced hepatocellular carcinoma

21 January 2018

1 reference

Hallmarks of Cancer: The Next Generation

21 January 2018

1 reference

Pivotal role of mTOR signaling in hepatocellular carcinoma

21 January 2018

1 reference

mTOR and P70 S6 kinase expression in primary liver neoplasms

21 January 2018

1 reference

Mammalian target of rapamycin pathway activity in hepatocellular carcinomas of patients undergoing liver transplantation

21 January 2018

1 reference

Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma

21 January 2018

1 reference

Monitoring of inosine monophosphate dehydrogenase activity in mononuclear cells of children with acute lymphoblastic leukemia: enzymological and clinical aspects

21 January 2018

1 reference

Analysis of risk factors for tumor recurrence after liver transplantation for hepatocellular carcinoma: key role of immunosuppression

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1002/LT.23806

1 reference

30 August 2017

1 reference

PubMed ID

24376158